Leveling cancer with IL-15

IL-15 Agonists: The Cancer Cure Cytokine.

The immune stimulatory cytokine interleukin-15 was recognized as one of the most promising cancer cure drug in an NIH guided review and is currently in clinical trial alone or as an adjuvant for certain types of metastatic solid tumors. IL-15 is an essential survival factor for natural killer (NK), natural killer-like T (NKT), and CD44hi memory CD8 T cells. The bioactivity of IL-15 in vivo is c...

Luminosity leveling with angle

The very high luminosity foreseen for the LHC luminosity upgrade entails in all cases a significant luminosity decrease during a few hours run. We present in this note a new method of luminosity leveling, based on the on-line adjustment of the crossing angle, while keeping the optics unchanged. It is implemented using the D0 dipole of a possible Early Separation Scheme and an orbit corrector. T...

Combined IL-15/IL-15R Immunotherapy Maximizes IL-15 Activity In Vivo

IL-23/IL-27 Ratio in Peripheral Blood of Patients with Breast Cancer

Background: Interleukin (IL)-23 and IL-27 are two IL-12-related cytokines which their function may dramatically influence the inflammatory response to tumor development. IL-12 and IL-27 seem to have antagonistic roles with IL-23 in tumor site. In this study, IL-23 and IL-27 mRNA expressions were analyzed in peripheral blood of patients with breast cancer and healthy volunteers using quantitativ...

Whole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15

Cancer immunotherapy (passive or active) involves treatments which promote the ability of the immune system to fight tumor cells. Several types of immunotherapeutic agents, such as monoclonal antibodies, immune checkpoint inhibitors, non-specific immunomodulatory agents, and cancer vaccines are currently under intensive investigation in preclinical and clinical trials. Cancer vaccines induce pe...